Brought to you by 
Perlegen and Mitsubishi in cross-licensing metabolic deal
12 Jul 2005
Executive Summary
In a cross-licensing agreement, Perlegen Sciences (pharmacogenetics; Affymetrix spin-off) has gained exclusive worldwide development and commercialization rights, excluding Asia, to Mitsubishi Pharma's MCC-555 (netoglitazone) to treat diabetes and other metabolic disorders. In turn, Mitsubishi gets exclusive rights in Asia to Perlegen's predictive genetic markers for use with MCC-555.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Alliance
- Product or Technology Swap
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Perlegen and Mitsubishi in cross-licensing metabolic deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice